The Food and Drug Administration rejected Eagle Pharmaceuticals Inc.'s (Nasdaq: EGRX) heat stroke treatment Ryanodex. The stock price collapsed $16.67 to close at $53.37.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|